Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Merck
Mallinckrodt
McKinsey
Boehringer Ingelheim
Medtronic
Baxter

Last Updated: November 13, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for Cebranopadol

See Plans and Pricing

« Back to Dashboard

What is the drug development status for Cebranopadol?

Cebranopadol is an investigational drug.

There have been 7 clinical trials for Cebranopadol. The most recent clinical trial was a Phase 3 trial, which was initiated on November 1st 2013.

The most common disease conditions in clinical trials are Chronic Pain, Substance-Related Disorders, and Peripheral Nervous System Diseases. The leading clinical trial sponsors are Grünenthal GmbH, Forest Laboratories, and [disabled in preview].

There are forty-one US patents protecting this investigational drug and nine hundred and thirty-three international patents.

Recent Clinical Trials for Cebranopadol
TitleSponsorPhase
CORAL XT - Open-label Extension Trial of the CORAL TrialGrünenthal GmbHPhase 3
CORAL - Cebranopadol Versus Morphine Prolonged-release in Patients With Chronic Moderate to Severe Pain Related to CancerGrünenthal GmbHPhase 3
Cebranopadol Efficacy and Safety in Diabetic Patients Suffering From Chronic Pain Caused by Damage to the NervesForest LaboratoriesPhase 2

See all Cebranopadol clinical trials

Clinical Trial Summary for Cebranopadol

Top disease conditions for Cebranopadol
Top clinical trial sponsors for Cebranopadol

See all Cebranopadol clinical trials

US Patents for Cebranopadol

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Cebranopadol   Start Trial Cebranopadol for treating pain in subjects with impaired hepatic and/or impaired renal function GRUNENTHAL GMBH (Aachen, DE)   Start Trial
Cebranopadol   Start Trial Abuse-proofed dosage form GRUNENTHAL GMBH (Aachen, DE)   Start Trial
Cebranopadol   Start Trial Thermoformed, tamper-resistant pharmaceutical dosage form containing zinc GRUENENTHAL GMBH (Aachen, DE)   Start Trial
Cebranopadol   Start Trial Pharmaceutical composition comprising (1r,4r)-6'-fluoro-N,N-dimethyl-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexa- ne-1,1'-pyrano-[3,4,b]indol]-4-amine and a propionic acid derivative Gruenenthal GmbH (Aachen, DE)   Start Trial
Cebranopadol   Start Trial Hot-melt extruded pharmaceutical dosage form GRUENENTHAL GMBH (Aachen, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Cebranopadol

Drugname Country Document Number Estimated Expiration Related US Patent
Cebranopadol Australia 2016208779 2035-01-23   Start Trial
Cebranopadol Canada 2974578 2035-01-23   Start Trial
Cebranopadol China 107427493 2035-01-23   Start Trial
Cebranopadol Eurasian Patent Organization 201791662 2035-01-23   Start Trial
Cebranopadol European Patent Office 3247352 2035-01-23   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Colorcon
Express Scripts
McKinsey
Mallinckrodt
Merck
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.